Krystal Biotech, Inc. KRYS

Krystal Biotech (KRYS) has further room for gains driven by Vyjuvek, its treatment for the rare blis

Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and crypto all at once.

Krystal Biotech stock has delivered a very large 5 year return while recent valuation checks and the latest share price action suggest the current market price may already be baking in high expectations. Krystal Biotech has returned roughly 5x over the past 5 years, which puts extra focus on whether the current share price still offers an appealing entry point or mainly reflects past success. Ongoing adoption of its genetic medicine platform can support the current valuation, while concerns...

Moby summary of Krystal Biotech, Inc.'s Q2 2026 earnings call

Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.

Krystal Biotech Inc (KRYS) reports strong Q2 2026 results with $119.2 million in global revenue, exceeding patient penetration goals and advancing its pipeline toward multiple registrational studies.

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

Top-notch biotech stocks TG Therapeutics and Twist Bioscience diverged Monday on mixed earnings reports.

Krystal Biotech, Inc. (NASDAQ:KRYS) reported second-quarter 2026 results on Monday that exceeded earnings expectations but fell short of Wall Street’s revenue estimates, sending the stock down 7.